CASODEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Casodex, and when can generic versions of Casodex launch?
Casodex is a drug marketed by Ani Pharms and is included in one NDA.
The generic ingredient in CASODEX is bicalutamide. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bicalutamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Casodex
A generic version of CASODEX was approved as bicalutamide by ACCORD HLTHCARE on July 6th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CASODEX?
- What are the global sales for CASODEX?
- What is Average Wholesale Price for CASODEX?
Summary for CASODEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 144 |
| Clinical Trials: | 102 |
| Patent Applications: | 4,532 |
| Drug Prices: | Drug price information for CASODEX |
| What excipients (inactive ingredients) are in CASODEX? | CASODEX excipients list |
| DailyMed Link: | CASODEX at DailyMed |
Recent Clinical Trials for CASODEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| University of California, San Francisco | Phase 1 |
| Radboud University Medical Center | Phase 2 |
Pharmacology for CASODEX
| Drug Class | Androgen Receptor Inhibitor |
| Mechanism of Action | Androgen Receptor Antagonists |
US Patents and Regulatory Information for CASODEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CASODEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Ani Pharms | CASODEX | bicalutamide | TABLET;ORAL | 020498-001 | Oct 4, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CASODEX
See the table below for patents covering CASODEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | S61118324 | NOVEL THERAPEUTICAL COMPOSITION USING LH_RH OR AGONIST | ⤷ Sign Up |
| Philippines | 19294 | TREATMENT METHOD | ⤷ Sign Up |
| Spain | 8601106 | ⤷ Sign Up | |
| Finland | 832644 | ⤷ Sign Up | |
| Canada | 1249823 | ACYLANILIDES AYANT DES PROPRIETES ANTIANDROGENES (ACYLANILIDES HAVING ANTIANDROGENIC PROPERTIES) | ⤷ Sign Up |
| Greece | 79232 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CASODEX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0100172 | 97C0010 | Belgium | ⤷ Sign Up | PRODUCT NAME: BICALUTAMIDUM; NAT. REGISTRATION NO/DATE: 624 S 291 F 3 19961014; FIRST REGISTRATION: GB 12619/0102 19950223 |
| 0100172 | SPC/GB95/015 | United Kingdom | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
